GaBI Journal (official Journal of the Generics and Biosimilars Initiative) is an independent and peer reviewed academic Journal, which encompasses all aspects of generic and biosimilar medicines development and use, from fundamental research up to clinical application and policies.
The mission of GaBI Journal is to provide an independent, high quality, authoritative, and peer reviewed platform for the publication of scientific articles concerning any aspect of the research into and development of cost-effective medicines, irrespective of their source.
This Open Access journal will thus make information on pharmaceutical innovation and developments in generic and biosimilar medicines accessible to everyone, including physicians, pharmacists and nurses, patients/consumers, drug developers, third-party payers, legislators and assessors.
This is achieved by:
- independent peer review
- collaboration with all relevant stakeholders (physicians/prescribers, regulatory authorities, industry, third-party payers and governments)
- publishing via open access channels, both in print and electronically.
Scope and Profile
The scope of GaBI Journal is broad and of interest and relevance to professionals active in clinical practice, pharmaceutical science, and policy. Materials published in GaBI Journal include high quality research reports, literature reviews and case studies, all of which are peer reviewed.
Manuscripts on all aspects of generic and biosimilar medicines, covering areas in clinical, fundamental, technical, manufacturing, bi-processing, economic and social aspects of pharmaceuticals and therapeutics are welcome. In addition, high quality work submitted in other formats, for example, scientific and evidence-based commentaries, may also be considered. In all cases, the emphasis is on quality, originality and knowledge contribution to those involved in health care.
All manuscripts submitted to GaBI Journal are subject to a rigorous peer review process. GaBI Journal plans to be indexed in PubMed within two years, and that indexing will be retrospective.
GaBI Journal is published quarterly from 2012. All articles are published in English.
GaBI Journal aims to educate and raise trust in safe and cost-effective use of medicines for healthcare professionals.
To achieve this, GaBI Journal publishes high quality, peer reviewed and independent scientific articles on all aspects of generic and biosimilar medicines, including but not limited to the development of formulations, production, testing including equivalence – in vivo and in vitro, model development, regulatory issues, supply chain management, and pharmacoeconomics, through the support of experts who are highly motivated to share their knowledge and professional experience.
In addition, GaBI Journal endeavours to publish regulatory guidelines and legislation in an abbreviated, simplified format as short reports, facilitating an easier and wider understanding of the technical and complicated official documentation.
GaBI Journal strives to satisfy the needs of a wide readership, offering high quality relevant reports, studies, analyses… Read more
GaBI Journal adheres to the standard of the ICMJE – Uniform Requirements for Manuscripts Submitted to… Read more
GaBI Journal’s Executive Editorial Board comprises the Editor-in-Chief, Deputy Editor-in-Chief, two Associate Editors… Read more
International Editorial Advisory Board
This international board of reputable scientists acts independently and represents the interests of the different parties… Read more
Peer Review Policy
All manuscripts submitted to GaBI Journal are subject to a rigorous peer review process. We welcome suggestions for… Read more
In May each year, the Editor-in-Chief of GaBI Journal, the Editorial Board and the editorial team meet in Brussels… Read more
GaBI Journal plans to be indexed in PubMed within two years, and that indexing will be retrospective… Read more